Home / Ceftazidime / United States
US ATC J01DD02 · updated 2 Nov 2026
Ceftazidime shortage in United States
Is there a Ceftazidime shortage in United States?
Yes. As of 2 Nov 2026, 2 Ceftazidime products are reported short in United States, the first since 14 Nov 2025. No return date has been given. Main reason: not stated.
Also short in Italy, Spain, Belgium, Japan. All countries.
Affected products in United States
| Country | Product | Company | Since | Expected back | Reason |
|---|---|---|---|---|---|
| US | Tazicef, Injection, 1 g (NDC 0409-5092-16) discontinuation | Hospira, Inc., a Pfizer Company | 14 Nov 2025 | not given | Not stated |
| US | Tazicef, Injection, 2 g (NDC 0409-5093-11) discontinuation | Hospira, Inc., a Pfizer Company | 14 Nov 2025 | not given | Not stated |
Source
U.S. Food and Drug Administration (FDA), Drug Shortages via openFDA. Official list. Shortages the FDA lists as current, plus products to be discontinued; one row per package (NDC).